Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
October 25th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD
Representatives from 3 payers who partnered with providers on the Oncology Care Model (OCM) took the stage at Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform to outline their experience with OCM and how it has differed from other care models.
Terrill Jordan: Education and Data Are Key for OCM Success
October 25th 2017

Terrill Jordan: Education and Data Are Key for OCM Success

Education is key to succeed in the Oncology Care Model, but presenting data in a simple format for clinicians to use is also critical, said Terrill Jordan, CEO, of Regional Cancer Care Associates.
Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia
October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez
Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25th 2017

Physicians Need Clearer Metrics Before Taking on 2-Sided Risk

Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.
Site Logo
October 25th 2017

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma

Julia Thornton Snider, PhD Katharine Batt, MD, MSc Yanyu Wu, PhD Mahlet Gizaw Tebeka, MS Seth Seabury, PhD
Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.
Site Logo
October 24th 2017

Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM

The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of patients and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.
Site Logo
October 24th 2017

Will 2-Sided Risk Be a Reality in OCM?

Kelly Davio
With the Oncology Care Model now in its second year, 3 representatives discussed learnings and how the program can change, as well as incentivizing physicians to accept 2-sided risk, the ability to engage additional payers, and the future of oncology bundle payments.
Site Logo
October 24th 2017

How Has the OCM Evolved? Year 1 Provider Updates

Surabhi Dangi-Garimella, PhD
Participants from 2 oncology community practices—an oncologist–administrator combination—shared their experience with implementing the Oncology Care Model (OCM) with attendees at the Community Oncology Alliance’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24, in Tysons Corner, Virginia.
Site Logo
October 24th 2017

Study: Prophylactic Up-Front Locoregional Surgery Has No Survival Advantage

Jaime Rosenberg
The study found that prophylactic locoregional surgery (LRS) for asymptomatic patients with small intestinal neuroendocrine tumors (SI-NETs) provided no survival advantage compared with delayed LRS.
Site Logo
October 23rd 2017

Increased Insurance Coverage Seen Under the ACA for Patients With Cancer

Jaime Rosenberg
A new study has found that uninsurance rates declined the most in patients with distant disease and with lung and bronchial cancer. Hispanic patients also saw a large decrease in uninsurance rates.
Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News
October 21st 2017

Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: October 20, 2017
October 20th 2017

This Week in Managed Care: October 20, 2017

This week, the top managed care news included the bipartisan deal to stabilize the Affordable Care Act's insurance markets; coverage from the Academy of Managed Care Pharmacy 2017 Nexus; and a plan to reduce clinician burnout at the computer.
Site Logo
October 19th 2017

Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel

Surabhi Dangi-Garimella, PhD
Axicabtagene ciloleucel (Yescarta) has been approved to treat adult patients with diffuse large B-cell lymphoma who have not responded to or who have relapsed after at least 2 other kinds of treatment.
Site Logo
October 18th 2017

PD-1 Inhibitor Doubled Survival in Treatment-Naive Patients With mNSCLC

Surabhi Dangi-Garimella, PhD
The 2-year follow up results from the Keynote-024 trial were presented at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan.
Site Logo
October 18th 2017

Increasing Levels of CD8+ TILs Prolong Survival in High-Grade Serous Ovarian Cancer

Jaime Rosenberg
There is a relationship between CD8+ tumor infiltrating lymphocytes (TILs) and high-grade serous ovarian carcinoma (HGSOC) survival, according to a new study published in JAMA Oncology.
Site Logo
October 17th 2017

PBMs: Their Role, the Problems, and How Practices Can Work With Them

Ray Bailey, RPh Ricky Newton, CPA
Site Logo
October 17th 2017

Positive Quality Interventions: An Innovative Platform for Oncology Practice Collaboration

Joshua Nubla, PharmD Neal Dave, PharmD Michael Reff, RPh, MBA
An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care.
Site Logo
October 17th 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina
Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.
Site Logo
October 17th 2017

UK Patients With Head and Neck Cancer Will Soon Have Access to Nivolumab

Jaime Rosenberg
The immunotherapy drug, made by Bristol-Myers Squibb, is recommended for use within the Cancer Drug Fund.
Site Logo
October 16th 2017

Trends in Hospital–Physician Integration in Medical Oncology

Jeffrey D. Clough, MD, MBA Michaela A. Dinan, PhD Kevin A. Schulman, MD
The authors used Medicare claims data to examine trends in hospital–physician integration in high-volume specialties, including medical oncology.
Site Logo
October 16th 2017

St. Jude Study Questions Efficacy of the Flu Vaccine in Children With Leukemia

Surabhi Dangi-Garimella, PhD
The study found that young patients with leukemia who have been vaccinated against the influenza virus are as susceptible to develop flu as their unvaccinated peers.
Site Logo
October 16th 2017

Pharmacy Team Engagement in Navigating the Revenue Cycle for High-Cost Medications in Patients With Cancer

Brandon R. Shank, PharmD, MPH, BCOP Phuoc Anh (Anne) Nguyen, PharmD, MS, BCPS Emily C. Pherson, PharmD, BCPS
With the clinical and financial implications of high-cost medications, and their impact on health system revenue, it is of utmost importance for all key stakeholders to be engaged in the complex revenue cycle.
Site Logo
October 16th 2017

Patients With Early Small Cell Lung Cancer Respond Favorably to Opdivo, Yervoy Combo

Jaime Rosenberg
The study showed that using tumor mutation burden (TMB) can be beneficial for predicting patient response to the combination of 2 immuno-oncology therapies.
Site Logo
October 13th 2017

Diagnosing and Treating Neutropenia: Q&A With Dr Daniel J. DeAngelo

Before treating certain patients, Daniel J. DeAngelo, MD, JD, of Harvard Medical School and the Dana-Farber Cancer Institute, will council them on the risk of developing neutropenia, which can result in hospitalization or even an intensive care stay.
Site Logo
October 13th 2017

AJMC®tv Interviews, October 2017

The Center for Biosimilars® Laura Joszt, MA
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers-from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Site Logo
October 13th 2017

Medical World News®, October 2017

AJMC Staff
An update on the latest developments in the world of oncology care: product approvals, clinical developments, health policy changes, and more.
Site Logo
October 13th 2017

Stand Up To Cancer Awards $5.5 Million for Epigenetic Immunotherapy Trials

Jaime Rosenberg
While many lung and bladder cancer patients respond well to immunotherapy, they eventually succumb to the disease because the immune system can not detect the cancer cells. Two clinical trials will combine immunotherapy with epigenetic agents in order to allow the immune system to recognize and destroy the cancer cells.
Site Logo
October 13th 2017

Pharmacy's Changing Role as Cancer Care Transitions From Infused to Oral Therapies

Stacey McCullough, PharmD Ricky Newton, CPA
The advent of oral oncolytics has changed the pharmacy's role in patient care beyond compounding infusions. Pharmacy staff now routinely engage patients, assessing adherence and tolerance to therapy as well as helping them navigate prescription benefits.
Site Logo
October 11th 2017

Deficient Mismatch Repair Extends Disease-Free Survival in CRC

Jaime Rosenberg
Patients with stage III colon cancer with deficient DNA mismatch repair (MMR) genes who are treated with FOLFOX have a more favorable prognosis than those with proficient MMRs.
Site Logo
October 11th 2017

A Reproductive Endocrinologist Discusses Need to Cover Fertility Intervention in Cancer Care

Surabhi Dangi-Garimella, PhD
The American Journal of Managed Care® spoke with Jane L. Frederick, MD, FACOG, a reproductive endocrinologist and fertility specialist, about the changing landscape of cancer treatment, partnering with oncologists, and helping patients gain financial assistance for their fertility preservation and treatment.
<1
...
646566676869707172
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo